BlinkLab has expanded its pivotal FDA autism diagnostic trial by adding the University of Nebraska Medical Center as a second U.S. clinical site, advancing toward broader validation and regulatory clearance.
- University of Nebraska Medical Center joins as second U.S. trial site
- Pilot phase with 100 participants nearing completion
- Main phase to enroll 750–900 children across up to 10 sites
- Focus on diverse pediatric populations for robust data
- FDA 510(k) submission expected in 2026
BlinkLab Expands Clinical Trial Network
BlinkLab Limited (ASX:BB1), a digital health company pioneering smartphone-based diagnostics for neurodevelopmental disorders, has announced a significant expansion of its U.S. clinical trial network. The University of Nebraska Medical Center (UNMC) has been engaged as the second clinical research site for the main phase of its FDA 510(k) autism diagnostic trial. This move underscores BlinkLab’s commitment to building a geographically diverse and scientifically rigorous study.
Pilot Phase Progress and Main Study Ambitions
The company is nearing completion of its pilot phase, which involves 100 participants and is designed to refine the study protocol and user experience. Following this, the main phase will scale up dramatically, targeting enrollment of between 750 and 900 children across multiple U.S. sites. BlinkLab aims to activate up to ten clinical sites nationwide, a strategy intended to accelerate recruitment and ensure the data reflects a broad spectrum of pediatric populations.
Strategic Importance of UNMC Partnership
UNMC was selected for its robust clinical trial infrastructure and proven ability to manage complex, multi-site research programs. Its access to specialized patient cohorts will be critical in generating high-quality, generalizable data that meets FDA standards. BlinkLab’s CEO, Dr. Henk-Jan Boele, highlighted that the partnership will help secure not only regulatory clearance but also long-term clinical adoption of the BlinkLab Dx 1 platform.
Looking Ahead to FDA Clearance and Market Impact
The distributed trial design is a deliberate effort to validate BlinkLab’s technology in real-world settings across diverse populations, a key factor for FDA approval and subsequent uptake by clinicians. The company anticipates submitting its final FDA 510(k) application in 2026, marking a critical milestone toward commercialisation. With early autism diagnosis traditionally delayed until around age five, BlinkLab’s smartphone-based tool offers a potentially transformative approach by enabling screening from as young as 18 months.
As BlinkLab scales its clinical trial network, investors and stakeholders will be watching closely for pilot phase results, additional site activations, and regulatory progress. The company’s blend of cutting-edge AI technology and strategic clinical partnerships positions it well in the evolving digital health diagnostics landscape.
Bottom Line?
BlinkLab’s expanding trial network sets the stage for a pivotal FDA submission and potential early autism diagnosis breakthrough.
Questions in the middle?
- How quickly will BlinkLab activate the remaining planned clinical sites?
- What insights will the pilot phase results reveal about the diagnostic tool’s accuracy?
- Could regulatory hurdles delay the anticipated 2026 FDA submission?